Geron (GERN) Amortization of Deferred Charges (2019 - 2026)
Geron's (GERN) quarterly Amortization of Deferred Charges came in at $286000.0 in Q1 2026, up 13.04% year-on-year from $253000.0 in Q1 2025, and up 1.06% quarter-over-quarter from $283000.0 in Q4 2025.
Geron (GERN) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Geron has disclosed Amortization of Deferred Charges across 8 years of filings, most recently posting $286000.0 for Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $286000.0, up 13.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 130.19% YoY), and the FY2025 annual result was $1.1 million, up 134.46% from the prior year.
- Amortization of Deferred Charges came in at $286000.0 for Q1 2026 at Geron, up from $283000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $802000.0 in Q1 2024 to a low of -$5.0 million in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $283000.0 (2025), against an average of $39058.8.
- Peak annual rise in Amortization of Deferred Charges reached 231.4% in 2024, while the deepest fall reached 1545.66% in 2024.
- Geron's Amortization of Deferred Charges stood at $224000.0 in 2022, then soared by 54.46% to $346000.0 in 2023, then sank by 1545.66% to -$5.0 million in 2024, then soared by 105.66% to $283000.0 in 2025, then gained by 1.06% to $286000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $286000.0 (Q1 2026), $283000.0 (Q4 2025), and $273000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286,000.00 |
| Mar 31, 2026 | 286,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 273,000.00 |
| Sep 30, 2025 | 273,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | -5.00 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | 402,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Mar 31, 2024 | 802,000.00 |
| Mar 31, 2024 | 802,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Dec 31, 2023 | 346,000.00 |